DX-104, a next-generation gOMV vaccine candidate for MenB, is planned for trials in China and Australia. The process scaled to 100 L, reached 98% purity, and is projected to yield over 1 million doses per batch.
Ralph Abraham resigned as CDC principal deputy director after less than two months, leaving the agency's top two positions vacant. The departure is part of broader HHS leadership changes under Secretary Robert F. Kennedy Jr.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07744347 |
A Clinical Study on Immunogenicity Persistence of Adsorbed 5-component Acellular Pertussis, Diphtheria and Tetanus Combined Vaccine |
NOT_YET_RECRUITING | |
| NCT07621341 |
Maternal Immunization With Tetanus Toxoid, Reduced Diphtheria Toxoid, Reduced-dose (2 µg) Recombinant Pertussis Vaccine (TdaP2gen) and Its Effect on the Immune Response in Thai Infants up to 15-18 Months Old |
NOT_YET_RECRUITING | PHASE4 |
| NCT06708286 |
A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component) |
COMPLETED | PHASE2/PHASE3 |
| NCT06056050 |
A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above) |
COMPLETED | PHASE1 |
| NCT05136599 |
Establishing a Controlled Human Infection Model of Bordetella Pertussis |
COMPLETED | PHASE1 |
